Research programme: anticancer natural human antibodies - Patrys

Drug Profile

Research programme: anticancer natural human antibodies - Patrys

Alternative Names: 3E10; 5C6; Deoxymab; PAT DX1 NP; PAT-BA1; PAT-BA2; PAT-BA4; PAT-CM1; PAT-DX1; PAT-NM1; PAT-NM2; PAT-PM1; PAT-PM2; PAT-SM3; PAT-SM4; PAT-SM5

Latest Information Update: 28 Dec 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator OncoMab GmbH; Patrys; Yale University
  • Developer Patrys; Yale University
  • Class Antibodies; Monoclonal antibodies
  • Mechanism of Action Cell death stimulants; DNA repair inhibitors; Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 11 Dec 2017 Preclinical development for Cancer is ongoing in Australia (Parenteral)
  • 16 Oct 2017 Patrys and Garvan Institute of Medical Research collaborate to conduct preclinical studies for PAT DX1
  • 14 Sep 2017 Pharmacodynamics data from a preclinical study in Cancer released by Patrys
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top